FDA批准擴大研究性胰臟癌藥物的使用範圍
.gov 表示它是官方網站。聯邦政府網站通常以 .gov 或 .mil 結尾。在分享敏感資訊之前，請確保您造訪的是聯邦政府網站。網站是安全的。
正文內容
FDA is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.
常見問題
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
